BioDelivery Sciences International Inc. (NASDAQ:BDSI) shares fell 5.9% during trading on Monday . The stock traded as low as $2.39 and last traded at $2.40, with a volume of 349,213 shares changing hands. The stock had previously closed at $2.55.

Several research firms recently commented on BDSI. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, July 27th. Janney Montgomery Scott restated a “hold” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $4.00 price target (down previously from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $8.25.

The stock’s market cap is $129.16 million. The stock’s 50 day moving average price is $2.43 and its 200-day moving average price is $3.04.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. The business earned $3 million during the quarter, compared to the consensus estimate of $2.96 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. BioDelivery Sciences International’s quarterly revenue was down 77.1% on a year-over-year basis. Equities research analysts forecast that BioDelivery Sciences International Inc. will post ($1.17) EPS for the current fiscal year.

A number of institutional investors have added to or reduced their stakes in BDSI. Bank of Montreal Can boosted its position in BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock valued at $3,971,000 after buying an additional 28,838 shares during the period. 1492 Capital Management LLC boosted its position in BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock valued at $2,580,000 after buying an additional 41,069 shares during the period. Royce & Associates LLC boosted its position in BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock valued at $7,127,000 after buying an additional 87,200 shares during the period. Sei Investments Co. boosted its position in BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock valued at $1,584,000 after buying an additional 233,519 shares during the period. Finally, Russell Frank Co boosted its position in BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock valued at $5,151,000 after buying an additional 394,272 shares during the period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.